# Apollon

> Apollon is a Korean-American medtech company building MOGLU, a needle-free continuous glucose monitor that reads blood sugar through the skin using Raman spectroscopy instead of a subcutaneous filament. Founded in Seoul in 2021 by Aram Hong and researchers tied to MIT and Asan Medical Center, the company is developing a compact wearable that reported accuracy comparable to leading CGMs in early MIT clinical testing, has been granted FDA Breakthrough Device designation, and won a 2025 CES Innovation Award.

- **Founded:** 2021
- **Headquarters:** Cambridge, Massachusetts, USA (with Seoul, South Korea)
- **Founders:** Aram Hong (CEO & Co-founder), Miyeon Jue (CTO & Co-founder), Jun Ki Kim (Co-founder & Scientific Advisor (Asan Medical Center Professor))
- **Team size:** ~37 employees
- **Products:** MOGLU, Raman-based non-invasive sensing platform
- **Notable:** Granted FDA Breakthrough Device designation for its non-invasive continuous glucose monitor, Won a 2025 CES Innovation Award (Digital Health), Reported a preclinical MARD of ~6.6% in early testing, competitive with commercial CGMs

## Products & services

- **MOGLU** — A needle-free continuous glucose monitor (roughly 40 x 30 x 16 mm) that detects glucose's Raman signal through the skin using a laser and machine learning, replacing the subcutaneous filament used by conventional CGMs. No skin puncture, no consumable sensor to replace.
- **Raman-based non-invasive sensing platform** — The underlying optics-and-AI platform that isolates weak glucose Raman signals from tissue and translates them into calibrated blood-glucose readings, developed with MIT's Laser Biomedical Research Center.

## Achievements

- Granted FDA Breakthrough Device designation for its non-invasive continuous glucose monitor
- Won a 2025 CES Innovation Award (Digital Health)
- Reported a preclinical MARD of ~6.6% in early testing, competitive with commercial CGMs
- All 279 data points fell within Zone A or B of the Clarke Error Grid in an IRB-approved MIT trial
- Established a multi-year research collaboration with MIT's Laser Biomedical Research Center (2023)

## Latest updates

- **2025-12** — MIT News highlighted non-invasive Raman imaging as a potential replacement for finger-prick glucose testing, work tied to Apollon's research collaboration.
- **2025-06** — Presented a comparison of its Raman-based non-invasive glucose sensor against commercial methods at an American Diabetes Association scientific session (abstract 1005-P).
- **2025-01** — Won a 2025 CES Innovation Award for the needle-free MOGLU continuous glucose monitor.
- **2024-12** — Announced as a CES 2025 Innovation Award honoree for its non-invasive CGM.
- **2024-04** — Raised a $1.93M seed round.
- **2023-08** — Announced a research collaboration with MIT to develop and run clinical trials of Raman-based non-invasive CGMs.

## Links

- Website: https://apollon.bio
- LinkedIn: https://www.linkedin.com/company/apollonbio/

---

Profile page: https://yespress.io/apollon
Published by YesPress — https://yespress.io
Last updated: 2026-07-07